Panacur Equine Oral Paste 18.75% w/w

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Buy It Now

Active ingredient:

Fenbendazole

Available from:

MSD Animal Health UK Limited

ATC code:

QP52AC13

INN (International Name):

Fenbendazole

Pharmaceutical form:

Oral paste

Prescription type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapeutic group:

Horses

Therapeutic area:

Anthelmintic

Authorization status:

Authorized

Authorization date:

1993-01-29

Summary of Product characteristics

                                Revised: April 2021
AN: 02063/2020
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Oral Paste 18.75% w/w
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 24g syringe contains:
Active substance(s)
% w/w
Fenbendazole
18.75
Excipient(s)
Methyl Parahydroxybenzoate
0.17
Propyl Parahydroxybenzoate
0.016
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral paste.
A white to light grey homogenous paste.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and other equines
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the treatment and control of adult
and immature
roundworms of the gastro-intestinal tract in horses and other equines.
Panacur
also has an ovicidal effect on nematode eggs.
Panacur effectively treats and controls the following roundworm
infections:
Large strongyles (adults and migrating larval stages of _S.vulgaris_;
adults and tissue
larval stages of _S.edentatus_).
Benzimidazole susceptible adult and immature small strongyles
(Cyathostomes),
including encysted mucosal 3rd and 4th stage larvae; it is also
effective against
encysted inhibited 3rd stage larvae in the mucosa.
Revised: April 2021
AN: 02063/2020
Page 2 of 6
Adult and immature Oxyuris spp.,Strongyloides spp. and _Parascaris
equorum._
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the
risk of development of resistance and could ultimately result in
ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an
extended period of time.
•
Under
dosing,
which
may
be
due
to
underestimation
of
body
weight,
misadministration of the product, or lack of calibration of the dosing
device (if
any).
Suspected
clinical
cases
of
resistance
to
anthelmintics
should
be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction
Test).
Where
the
results
of
the
test(s)
strongly
suggest
resista
                                
                                Read the complete document
                                
                            

Search alerts related to this product